

Date: 4th March 2014

Minutes: Final

Guideline Development Group Meeting 8 **Type 2 Diabetes**

Place: *Mercure
Portland Street
Manchester*

Present: Damien Longson (Chair)
Ian Lewin (IL)
Sailesh Sankar (SS)
Maria Cowell (MC)
Jonathan Roddick (JR)
Yvonne Johns (YJ)
Natasha Marsland (NM)
Prunella Neale (PN)
Indranil Dasgupta (ID) – co-opted expert
Amanda Adler (AA)
Natasha Marsland (NM)
Andrew Farmer (AFr)

Apologies: Natasha Jacques (NJ)
Anne Fittock (AF)

In attendance:

NICE Staff:

Abitha Senthinathan (AS)
Stephanie Mills (SM)
Mike Heath (MH)
Steven Ward (SWard)
Gabriel Rogers (GR)
Sheryl Warttig (SW)

Apologies:

Clifford Middleton (CM)
Toni Tan (TT)

Observers:

N/A		
-----	--	--

Afr to introduce himself to the group. Apologies were received from NJ and AF. All committee members declared that they knew of no personal specific, personal non-specific, non-personal specific or non-personal non-specific interest in the development of this guideline beyond those which had previously been declared.

DL asked whether the group agreed that the minutes of the previous meeting were a clear and accurate record. The minutes were agreed by all present. The objectives of the day were to discuss evidence on the long term adverse effects of pharmacological treatment, learn about progress on the analyses for pharmacological management, and also for the GDG to offer expertise on a number of guideline queries including feedback from the diabetes oversight group (DOG).

JR and SS gave an update on the discussions of the DOG, and explained that these may need to be considered by the GDG during the business of the day.

2. SW began the meeting by presenting the types of studies which had been included in the evidence review for long term adverse effects. The GDG discussed the benefits and drawbacks of registry data. The GDG discussed some of the biases of the evidence base.
3. Following this session, AS presented progress on the analyses for pharmacological management, including issues of categorisation for drugs included within the synthesis.
4. SM presented to the group on comments that had come back for the DOG on the recommendations for target values and erectile dysfunction. The group considered the rationale behind their decisions and came to a conclusion on the final recommendations. The GDG also helped to identify the clinical appropriateness of existing recommendations from the old type 2 diabetes guideline. The GDG were also reminded that the lipids and chronic kidney disease guidelines are out for consultation and that these two guidelines would update sections from clinical guideline 66 (CG66).
5. DL thanked the group for their hard work. SM let the group know that the next meeting would be held in Manchester on 28th April 2014.

Date, time and venue of the next meeting

Mon 28th April 2014 –NICE, Manchester